GE HealthCare unveils new mammography system
November 26, 2024
GE HealthCare (Nasdaq:GEHC) today announced its new Pristina Via mammography system designed to enhance the screening experience.
GE HealthCare (Nasdaq:GEHC) today announced its new Pristina Via mammography system designed to enhance the screening experience.
iCad (Nasdaq:ICAD) announced today that the FDA cleared its ProFound Detection version 4.0 for digital breast tomosynthesis (DBT).
The drug-device combination developed by MIT spinout Lumicell is poised to reduce repeat surgeries and ensure more complete tumor removal.
SimBioSys announced that it received its second FDA 510(k) clearance for TumorSight Viz to expand its use by breast surgeons in the U.S.
Mira has launched Mira Hormone Monitor: Menopause Transitions Kit to help women aged 35 and older track their hormones to spot early signs of perimenopause and manage them effectively.
Promising findings by researchers at Baylor College of Medicine and collaborating institutions could lead to the development of a non-invasive stool test and a new therapy for endometriosis, a painful condition that affects nearly 200 million women worldwide. The study appears in the journal Med.
The 3D capabilities are part of Siemens’ first completely redesigned mammography platform in over a decade.
Motiva is the first new breast implant to receive premarket approval since 2013, according to Establishment Labs, and enters a market reshaped by safety issues linked to other products.
Femasys today announced it received FDA 510(k) clearance for its FemChec contrast-generating device that checks fallopian tubal status.
For the first time, neuroscientists have developed a way to address debilitating PMS and menstrual pain symptoms without relying on drugs, hormones, or enduring severe side effects.